Tag: ReCor Medical
CMS grants transitional pass-through payment for Medtronic’s Symplicity Spyral and Recor’s...
The Centers for Medicare and Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for Medtronic's Symplicity Spyral renal denervation (RDN) catheter and Recor...
Vascular News’ top 10 most popular stories of July 2024
Several company updates including Series A funding for Endoron Medical, new insights on the role of machine learning in determining endovascular aneurysm repair (EVAR)...
First patients treated in US GPS study of Paradise renal denervation...
The first patients in the USA have been treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS), a real-world study...
FDA panel votes favourably on safety and efficacy of Paradise renal...
The US Food and Drug Administration (FDA) Circulatory Systems Devices Panel of the Medical Devices Advisory Committee yesterday (22 August) voted that there is...
Results on ReCor Medical’s Paradise ultrasound renal denervation system published in...
ReCor Medical and its parent company, Otsuka Medical Devices, recently announced that primary endpoint results from the RADIANCE II pivotal trial were published in...
ReCor appoints Lara Barghout to lead commercialisation of Paradise renal denervation...
ReCor Medical and its parent company Otsuka Medical Devices have announced the appointment of Lara Barghout as president and chief executive officer of ReCor.
Barghout...
Otsuka Medical Devices and ReCor Medical submit premarket approval of Paradise...
Otsuka Medical Devices and ReCor Medical, a subsidiary of Otsuka, announce the filing of the premarket approval (PMA) application to the US Food and Drug...
ReCor Medical announces consistent reduction of blood pressure in pooled analysis...
ReCor Medical and its parent company, Otsuka Medical Devices, announced consistent and significant blood pressure-lowering results across a range of patients with uncontrolled hypertension,...
Ultrasound renal denervation meets primary efficacy endpoint in RADIANCE II study
ReCor Medical and Otsuka Medical Devices have announced that the RADIANCE II US Food and Drug Administration (FDA) investigational device exemption (IDE) pivotal trial...
